BURROUGHS WELLCOME SEEKS INJUNCTION AGAINST SMITHKLINE FAMVIR SALES
This article was originally published in The Tan Sheet
Executive Summary
BURROUGHS WELLCOME SEEKS INJUNCTION AGAINST SMITHKLINE FAMVIR SALES, claiming that the new herpes zoster drug infringes two patents held by the company covering its antiviral drug, Zovirax (acyclovir). In an Aug. 23 complaint fried in Raleigh, N.C. federal court, Burroughs Wellcome urged the court to find that SmithKline Beecham's manufacture, use or sale of Famvir (famciclovir) infringes its patents. Wellcome is seeking a permanent injunction against the drug's use and treble damages with interest. The company is requesting a jury trial.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning